Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Compass Therapeutics (CMPX) Accumulated Depreciation & Amortization (2022 - 2026)

Compass Therapeutics' Accumulated Depreciation & Amortization history spans 5 years, with the latest figure at $6.7 million for Q1 2026.

  • On a quarterly basis, Accumulated Depreciation & Amortization changed 0.23% to $6.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.7 million, a 0.23% change, with the full-year FY2025 number at $6.6 million, up 4.34% from a year prior.
  • Accumulated Depreciation & Amortization hit $6.7 million in Q1 2026 for Compass Therapeutics, roughly flat from $6.6 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CMPX hit a ceiling of $6.7 million in Q3 2024 and a floor of $5.6 million in Q4 2022.
  • Historically, Accumulated Depreciation & Amortization has averaged $6.3 million across 5 years, with a median of $6.5 million in 2024.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 12.55% in 2023 and later fell 1.43% in 2025.
  • Tracing CMPX's Accumulated Depreciation & Amortization over 5 years: stood at $5.6 million in 2022, then rose by 12.55% to $6.3 million in 2023, then increased by 1.5% to $6.4 million in 2024, then rose by 4.34% to $6.6 million in 2025, then rose by 0.23% to $6.7 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for CMPX at $6.7 million in Q1 2026, $6.6 million in Q4 2025, and $6.6 million in Q3 2025.